BREAST CANCER TREATMENT AT CMN HOSPITAL
Triple-Negative Breast Cancer Treatment
Individualized 28-day inpatient treatment for women with triple-negative breast cancer under the direction of Dr. Edgar Payán within CMN Hospital.
Understanding Triple-Negative Breast Cancer
Triple-negative breast cancer, or TNBC, means the cancer cells test negative for estrogen receptors (ER), progesterone receptors (PR), and HER2. These three findings matter because many breast cancer treatments are designed specifically around one or more of those receptors.
A triple-negative diagnosis therefore gives Dr. Edgar Payán important information about the biology of the cancer, but it is only one part of the medical picture. He also reviews the pathology, stage and extent of disease, imaging, previous treatments, laboratory findings, current health, medications, treatment tolerance, and clinical condition before developing the treatment protocol.
The 4-Week Inpatient Program
Dr. Payán treats triple-negative breast cancer within CMN Hospital’s full 28-day Advanced Alternative Cancer Treatment Program.
The four-week inpatient stay gives him time to sequence treatment, follow laboratory findings and clinical response, monitor how the patient is tolerating therapy, and adjust the protocol throughout the stay. Treatment is individualized case by case rather than assigned from a fixed schedule.
For a woman with TNBC, the program can bring together therapies directed toward cancer-cell biology, immune recognition, immune-cell production, oxygenation, cellular metabolism, nutrition, detoxification, and overall medical support.
Cellular and Immune Therapies
Dendritic Cell Therapy
Dendritic cells are specialized messenger cells of the immune system. They collect cancer-related antigens and present that identifying information to T cells, helping prime those T cells to recognize the same cancer-related markers as they circulate through the body. The treatment goal is more specific cancer recognition and a directed immune response.
Autologous Bone Marrow Stem Cell Therapy
For women who are appropriate candidates, Dr. Payán can incorporate the patient’s own bone marrow stem and progenitor cells during the final stage of the program. These young blood-forming cells are the source from which the body continually produces Natural Killer cells, T cells, B cells, dendritic cells, neutrophils, monocytes and macrophages, red blood cells, platelets, and other blood and immune cells.
The patient’s bone marrow is collected under short sedation, processed in the hospital laboratory, and centrifuged to separate and concentrate the blood-forming cell fraction. A hematopoietic growth factor is used with the collected healthy cells to increase that cell population before the patient’s own prepared cells are returned through an IV into the bloodstream.
TRIPLE-NEGATIVE BREAST CANCER RESEARCH
Blue Scorpion Venom and TNBC
Blue Scorpion Venom derived from Rhopalurus junceus has been studied directly in triple-negative breast cancer cells.
In a published 2017 laboratory study using the human MDA-MB-231 triple-negative breast cancer cell line, researchers found that Rhopalurus junceus venom reduced cancer-cell viability and induced apoptosis, the programmed cell-death process used by the body to remove damaged or abnormal cells.
The researchers identified activity within the mitochondrial pathway of apoptosis. They reported increased expression of p53, bax, noxa, puma, caspase-3, and p21, together with reduced expression of the anti-apoptotic factors bcl-2 and bcl-xl.
Earlier research also evaluated the venom against a panel of human cancer cell lines that included the breast cancer cell lines MDA-MB-231 and MDA-MB-468. A later mammary-tumor study reported both laboratory cytotoxicity and inhibition of tumor progression in an animal model, including reductions in Ki-67 and CD31 within tumor tissue.
This research is particularly relevant to Dr. Payán’s treatment planning for triple-negative breast cancer because TNBC lacks the estrogen, progesterone, and HER2 targets found in other breast cancer subtypes.
Published Research
Triple-Negative Breast Cancer
Díaz-García A, Ruiz-Fuentes JL, Rodríguez-Sánchez H, Fraga Castro JA. “Rhopalurus junceus scorpion venom induces apoptosis in the triple negative human breast cancer cell line MDA-MB-231.” Journal of Venom Research. 2017;8:9–13. PMID 29285349. PMCID PMC5735679.
Human Breast Cancer Cell Lines
Díaz-García A, Morier-Díaz L, Frión-Herrera Y, et al. “In vitro anticancer effect of venom from Cuban scorpion Rhopalurus junceus against a panel of human cancer cell lines.” Journal of Venom Research. 2013;4:5–12. PMID 23946884. PMCID PMC3717326.
Mammary Tumor Research
Díaz-García A, Ruiz-Fuentes JL, Frión-Herrera Y, et al. “Rhopalurus junceus scorpion venom induces antitumor effect in vitro and in vivo against a murine mammary adenocarcinoma model.” Iranian Journal of Basic Medical Sciences. 2019;22(7):759–765. PMID 32373297. PMCID PMC7196348. DOI 10.22038/ijbms.2019.33308.7956.
Continuing Blue Scorpion Venom Therapy at Home
When Blue Scorpion Venom Therapy is part of Dr. Payán’s protocol, the treatment does not end when the 28-day inpatient stay is completed. The patient goes home with the therapy and continues it according to the instructions provided by Dr. Payán as part of her individualized aftercare plan.
Begin With Dr. Payán’s Medical Review
Women considering CMN Hospital’s 28-day inpatient program begin by submitting recent medical records, pathology, receptor testing, imaging, laboratory findings, and treatment history for review.
Contact